Media Search:



Cell breakthrough in cancer fight

Australian researchers have made a breakthrough in the fight against cancer and are working to find a way to get the body's natural killer cells to eliminate cancerous cells.

Researchers at Melbourne's Peter MacCallum Cancer Centre have discovered a new molecule that a cancer cell can produce on its surface to convince the body's natural killer cells it poses no danger.

The research team, led by Dr Dan Andrews and Professor Mark Smyth from the Cellular Immunology Laboratory at the centre, says the cancer cells fool the body's natural immune defences into ignoring their threat.

Dr Andrews said the discovery would open the door to the development of new treatments to interrupt this deception.

The findings were published overnight in the prestigious scientific journal Nature Immunology.

Dr Andrews says each natural killer cell is part of a roving biological security team, performing sweeping scans by temporarily binding one of its receptors to a corresponding molecule on every cell's surface, like a key into a lock.

"When a cell becomes infected or damaged, it loses these surface molecules; when a natural killer cell cannot find a lock to bind to, it recognises that cell as a threat and destroys it," he says.

Researchers from around the world have been hunting for each lock to correspond to the 10 identified natural killer cell surface keys, but only investigating the MHC-I class of molecule, or classical MHC-I.

The lock Dr Andrews and his team have discovered, called H2-M3, is a non-classical MHC-I molecule.

"Now we have identified the role H2-M3 plays in cancer growth, we can learn more about how it binds to natural killer cell receptors and plan new therapies to specifically target these types of interactions," Dr Andrews said.

Originally posted here:
Cell breakthrough in cancer fight

Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver

BLUE BELL, Pa., Nov. 12, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its synthetic hepatitis B (HBV) therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine's potential to clear HBV infection and thereby prevent liver cancer in humans, an encouraging development given that nearly one-third of the world's population is infected with hepatitis B, with 400 million at risk of developing liver cancer.

Results from this preclinical study appear in the peer-reviewed journal, Cancer Gene Therapy, in an article entitled, "Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver."

In the study, Inovio researchers and collaborators constructed a DNA vaccine encoding an HBV core antigen using the SynCon vaccine technology and administered it via Inovio's proprietary electroporation-based delivery technology. Researchers observed that the vaccine induced strong "killer" T cells in an animal model. Importantly, those killer T cells, while found systemically, were also present in the liver and provided clearance of HBV antigen-expressing liver cells without inducing liver damage.

The company is also investigating additional HBV antigens to develop a multi-component vaccine that can provide the host immune system multiple targets to clear the hepatitis B virus and infected liver cells.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "Inovio has established a potent immune therapeutics platform. With our recent scientific breakthrough represented by our human data showing the powerful killing effect of T cells generated by our cervical dysplasia therapeutic vaccine, we are encouraged by the published preclinical results generated by our therapeutic vaccine against HBV. Hepatitis B is one of the most important global health problems, and we are excited by the prospect of addressing HBV and other chronic infectious diseases with our vaccines.

Scientific Discussion of Results

With a quarter of a billion people chronically infected worldwide and at risk of developing liver cancer, there is a critical need for an effective HBV therapeutic vaccine that can induce strong antigen-specific immune responses and subsequently deploy the immune responses towards the liver.

In this study, Inovio developed a synthetic DNA vaccine which is encoded for the HBcAg antigen and represents a consensus of the unique HBcAg DNA sequences of all major HBV genotypes (A through E). When delivered by electroporation, researchers first demonstrated that this vaccine elicited strong HBcAg-specific T cell and antibody responses in the periphery (outside of the liver) by ELISpot, ICS and cell proliferation assays. Researchers observed that the vaccination could also induce antigen-specific CD8 and CD4 T cells that produced both IFN-y and TNF-a in the liver, indicating a strong vaccine-induced T cell response was also present in the liver.

Furthermore, study researchers found the vaccine-specific T cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without any evidence of liver injury. Taken together, this is the first study to provide evidence that intramuscular immunization can induce killer T cells that can migrate to the liver and eliminate target cells.

About Hepatitis B and Liver Cancer

Read this article:
Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver

Rudra Productions – Video


Rudra Productions
Over the last 2 years, We have developed a wide range of websites using Flash, HTML, DHTML, PHP, including sites for startup companies and small businesses. Our core competency lies in Flash and e-learning projects, and We are seeking opportunities to build good animations for your business. We own employees whos having background in Web/Graphic Design along with Bachelors degree in Multimedia and Animation ( Digital Arts). We are comfortable with HTML5,CSS3, XML, J query, cross browser compatibility (ie6 to ie9, chrome, Mozilla Firefox, net scape, opera ) and on page SEO. I am trained in computer graphics packages such as Dreamweaver, Photoshop, Adobe Illustrator,,Sound forge, adobe premier, and other web development technologies like WordPress, Joomla, and Drupal.From:ameya rudrabhateViews:12 1ratingsTime:00:23More inFilm Animation

See original here:
Rudra Productions - Video

Joomla 3.0 – Login Module – Video


Joomla 3.0 - Login Module
Creating and publishing a Login Module in Joomla 3.0From:Brad BakerViews:28 0ratingsTime:00:51More inScience Technology

Continue reading here:
Joomla 3.0 - Login Module - Video

How to install Joomla on GreenGeeks with 1-click – Video


How to install Joomla on GreenGeeks with 1-click
A step-by-step guide on how to install Joomla on GreenGeeks using a 1-click installer. Drupal web hosting made easy with 300% green energy web hostingFrom:GreenGeeksWebHostingViews:1 0ratingsTime:03:21More inHowto Style

See the original post:
How to install Joomla on GreenGeeks with 1-click - Video